Christopher M Tully1,2, Andrea B Apolo3, Emily C Zabor4, Ashley M Regazzi1, Irina Ostrovnaya4, Helena F Furberg4, Jonathan E Rosenberg1,2, Dean F Bajorin1,2. 1. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Medicine, Weill Medical College of Cornell University, New York, New York. 3. Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: The current study compared the incidence of vascular thromboembolic events (VTEs) in patients with metastatic or unresectable urothelial carcinoma (UC) who were treated with gemcitabine and carboplatin (GCb); gemcitabine, carboplatin, and bevacizumab (GCbBev); or gemcitabine and cisplatin (GCis). METHODS: Patients with UC who were treated with GCbBev on protocol were analyzed prospectively and 2 contemporary control cohorts receiving GCb or GCis were evaluated retrospectively. VTE was defined as either venous or arterial (myocardial infarctions or cerebral vascular accidents) thrombosis. VTEs were considered to be related to treatment if they occurred during treatment or within 4 weeks of the completion of treatment. Associations with chemotherapy regimen were tested using either the Fisher exact test or Kruskal-Wallis test. Clinical factors associated with VTEs were analyzed using conditional logistic regression stratified by treatment regimen. RESULTS: Among 198 patients, VTEs occurred in 13 of 51 patients treated with GCbBev (26%), 22 of 92 patients treated with GCb (24%), and 8 of 55 patients treated with GCis (15%). Patient characteristics were significantly different between the treatment cohorts in terms of age, prior cystectomy, tumor location near pelvic vessels, Khorana risk group, and receipt of antiplatelet therapy. The incidence of VTE and type of VTE (arterial vs venous) did not differ by type of chemotherapy. Prior cystectomy was associated with an increased risk of VTE (odds ratio, 2.2; 95% confidence interval, 1.0-4.9 [P = .047]). CONCLUSIONS: The incidence of VTE in Cis-treated patients was similar to prior reports. However, the VTE rate in Cb-treated patients was > 20%, a figure not previously defined in patients with UC and higher than expected. This high incidence of both Cis-related and Cb-related VTEs warrants greater awareness by treating physicians and deserves further study. Cancer 2016;122:712-721.
BACKGROUND: The current study compared the incidence of vascular thromboembolic events (VTEs) in patients with metastatic or unresectable urothelial carcinoma (UC) who were treated with gemcitabine and carboplatin (GCb); gemcitabine, carboplatin, and bevacizumab (GCbBev); or gemcitabine and cisplatin (GCis). METHODS:Patients with UC who were treated with GCbBev on protocol were analyzed prospectively and 2 contemporary control cohorts receiving GCb or GCis were evaluated retrospectively. VTE was defined as either venous or arterial (myocardial infarctions or cerebral vascular accidents) thrombosis. VTEs were considered to be related to treatment if they occurred during treatment or within 4 weeks of the completion of treatment. Associations with chemotherapy regimen were tested using either the Fisher exact test or Kruskal-Wallis test. Clinical factors associated with VTEs were analyzed using conditional logistic regression stratified by treatment regimen. RESULTS: Among 198 patients, VTEs occurred in 13 of 51 patients treated with GCbBev (26%), 22 of 92 patients treated with GCb (24%), and 8 of 55 patients treated with GCis (15%). Patient characteristics were significantly different between the treatment cohorts in terms of age, prior cystectomy, tumor location near pelvic vessels, Khorana risk group, and receipt of antiplatelet therapy. The incidence of VTE and type of VTE (arterial vs venous) did not differ by type of chemotherapy. Prior cystectomy was associated with an increased risk of VTE (odds ratio, 2.2; 95% confidence interval, 1.0-4.9 [P = .047]). CONCLUSIONS: The incidence of VTE in Cis-treated patients was similar to prior reports. However, the VTE rate in Cb-treated patients was > 20%, a figure not previously defined in patients with UC and higher than expected. This high incidence of both Cis-related and Cb-related VTEs warrants greater awareness by treating physicians and deserves further study. Cancer 2016;122:712-721.
Authors: K Kröger; D Weiland; C Ose; N Neumann; S Weiss; C Hirsch; K Urbanski; S Seeber; M E Scheulen Journal: Ann Oncol Date: 2005-11-09 Impact factor: 32.976
Authors: Christelle Clément-Duchêne; Yelena Krupitskaya; Kristen Ganjoo; Philip Lavori; Alex McMillan; Atul Kumar; Gary Zhao; Sukhmani Padda; Lisa Zhou; Melanie San Pedro-Salcedo; A Dimitrios Colevas; Heather A Wakelee Journal: J Thorac Oncol Date: 2010-11 Impact factor: 15.609
Authors: Gabriella Zecchina; Paolo Ghio; Sandra Bosio; Marta Cravino; Clara Camaschella; Giorgio V Scagliotti Journal: Clin Lung Cancer Date: 2007-01 Impact factor: 4.785
Authors: V Lorusso; C F Pollera; M Antimi; G Luporini; C Gridelli; G L Frassineti; C Oliva; M Pacini; M De Lena Journal: Eur J Cancer Date: 1998-07 Impact factor: 9.162
Authors: Jorge D Ramos; Sarah K Holt; George R Schade; Matthew D Galsky; Jonathan L Wright; John L Gore; Evan Y Yu Journal: BJU Int Date: 2019-02-19 Impact factor: 5.588
Authors: Fern Anari; John O'Neill; Woonyoung Choi; David Y T Chen; Mohammed Haseebuddin; Alexander Kutikov; Essel Dulaimi; R Katherine Alpaugh; Karthik Devarajan; Richard E Greenberg; Marijo Bilusic; Yu-Ning Wong; Rosalia Viterbo; Jean H Hoffman-Censits; Costas D Lallas; Edouard J Trabulsi; Marc Smaldone; Daniel M Geynisman; Matthew Zibelman; Jianqing Lin; W Kevin Kelly; Robert Uzzo; David McConkey; Elizabeth R Plimack Journal: Eur Urol Oncol Date: 2018-06-06
Authors: Gopa Iyer; Christopher M Tully; Emily C Zabor; Bernard H Bochner; Guido Dalbagni; Harry W Herr; S Machelle Donat; Paul Russo; Irina Ostrovnaya; Ashley M Regazzi; Matthew I Milowsky; Jonathan E Rosenberg; Dean F Bajorin Journal: Clin Genitourin Cancer Date: 2020-03-06 Impact factor: 3.121
Authors: Steven P Grover; Yohei M Hisada; Raj S Kasthuri; Brandi N Reeves; Nigel Mackman Journal: Arterioscler Thromb Vasc Biol Date: 2021-02-11 Impact factor: 8.311